Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.

Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH, SIMPLIFY Study Group

Open source

DOI: 10.1016/s2213-2600(22)00434-9
Published: 2023 Apr
Container: The Lancet. Respiratory medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-22-00434-9,
  title = {Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.},
  author = {Mayer-Hamblett N and Ratjen F and Russell R and Donaldson SH and Riekert KA and Sawicki GS and Odem-Davis K and Young JK and Rosenbluth D and Taylor-Cousar JL and Goss CH and Retsch-Bogart G and Clancy JP and Genatossio A and O'Sullivan BP and Berlinski A and Millard SL and Omlor G and Wyatt CA and Moffett K and Nichols DP and Gifford AH and SIMPLIFY Study Group},
  year = {2023},
  journal = {The Lancet. Respiratory medicine},
  doi = {10.1016/s2213-2600(22)00434-9},
  url = {https://doi.org/10.1016/s2213-2600(22)00434-9}
}

RIS

TY  - JOUR
TI  - Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
AU  - Mayer-Hamblett N
AU  - Ratjen F
AU  - Russell R
AU  - Donaldson SH
AU  - Riekert KA
AU  - Sawicki GS
AU  - Odem-Davis K
AU  - Young JK
AU  - Rosenbluth D
AU  - Taylor-Cousar JL
AU  - Goss CH
AU  - Retsch-Bogart G
AU  - Clancy JP
AU  - Genatossio A
AU  - O'Sullivan BP
AU  - Berlinski A
AU  - Millard SL
AU  - Omlor G
AU  - Wyatt CA
AU  - Moffett K
AU  - Nichols DP
AU  - Gifford AH
AU  - SIMPLIFY Study Group
PY  - 2023
JO  - The Lancet. Respiratory medicine
DO  - 10.1016/s2213-2600(22)00434-9
UR  - https://doi.org/10.1016/s2213-2600(22)00434-9
ER  -

APA

N, M., F, R., R, R., SH, D., KA, R., GS, S., K, O., JK, Y., D, R., JL, T., CH, G., G, R., JP, C., A, G., BP, O., A, B., SL, M., G, O., CA, W., K, M., DP, N., AH, G., & Group, S. S. (2023). Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.. The Lancet. Respiratory medicine. https://doi.org/10.1016/s2213-2600(22)00434-9

Source records

pubmed · retrieved 2026-09-26T00:23:22.365Z
europe-pmc · retrieved 2026-09-26T00:23:22.366Z